Vanda Pharmaceuticals Inc. (VNDA) › Total AssetsVanda Pharmaceuticals Inc. (VNDA) — Total AssetsAnnual figures by period end, from SEC filings.2010-12-31: $213.10M2011-12-31: $182.62M2012-12-31: $135.45M2013-12-31: $143.35M2014-12-31: $171.70M2015-12-31: $213.05M2016-12-31: $210.37M2017-12-31: $205.43M2018-12-31: $332.13M2019-12-31: $483.75M2020-12-31: $533.46M2021-12-31: $593.79M2022-12-31: $634.25M2023-12-31: $648.44M2024-12-31: $656.20M2025-12-31: $488.95M$488.95M2010-12-31Total Assets (USD)2025-12-31Period endedTotal AssetsChange YoYSource filing2025-12-31$488.95M-25.5%2026-02-12Balance as of period end2024-12-31$656.20M+1.2%2026-02-12Balance as of period end2023-12-31$648.44M+2.2%2025-02-14Balance as of period end2022-12-31$634.25M+6.8%2024-02-08Balance as of period end2021-12-31$593.79M+11.3%2023-02-09Balance as of period end2020-12-31$533.46M+10.3%2022-02-24Balance as of period end2019-12-31$483.75M+45.7%2021-02-11Balance as of period end2018-12-31$332.13M+61.7%2020-02-26Balance as of period end2017-12-31$205.43M-2.4%2019-02-19Balance as of period end2016-12-31$210.37M-1.3%2018-02-15Balance as of period end2015-12-31$213.05M+24.1%2017-02-17Balance as of period end2014-12-31$171.70M+19.8%2016-02-12Balance as of period end2013-12-31$143.35M+5.8%2015-03-13Balance as of period end2012-12-31$135.45M-25.8%2014-02-25Balance as of period end2011-12-31$182.62M-14.3%2013-02-26Balance as of period end2010-12-31$213.10M—2012-03-09Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)